Folic acid and prevention of the neural tube defects
Authors:
E. Doležálková 1; V. Unzeitig 1,2,3
Authors‘ workplace:
Porodnicko-gynekologická klinika OU a FN, Ostrava, přednosta doc. MUDr. V. Unzeitig, CSc.
1; Gynekologicko-porodnická klinika MU a FN, Brno, přednosta prof. MUDr. P. Ventruba, DrSc., MBA
2; Centrum ambulantní gynekologie a primární péče, Brno, vedoucí lékař MUDr. V. Dvořák
3
Published in:
Ceska Gynekol 2014; 79(2): 134-139
Overview
Objective:
Overview of neural tube defect in relation to use of folic acid among fertile-age women.
Design:
Review article.
Setting:
Obstetrics and gynecology department OU and FN Ostrava.
Methods and results:
Neural tube defects (NTDs) are one of the most common birth defects in the Czech Republic. The relation between using of folic acid and decrease of the incidence NTDs was first described in 1965. Fertile-age women are not able to get enough folate from their diet, therefore right timing and proper dosing of folic acid is the object of numerous studies. Many countries started theirs food fortification programs because of the high percentage of unplanned pregnancies and often low compliance.
Conclusion:
The role of folic acid in prevention of NTDs is undeniable. Due to the large number of unplanned pregnancies long-term supplementation is recommended for all fertile-age women. If pregnancy is planned, the suplementation should begin at least one month before pregnancy. In both cases it is necessary to continue until the end of the week of 12. dosage should be individualized according to risk.
Keywords:
neural tube defects, risk factors, folic acid, suplementation, fortification
Sources
1. Bell, KN., Oakley, GP. Update on prevention of folic acid-preventable spina bifida and anencephaly. Birth Defects Research Part A: Clin Mol Teratol. 2009, 85(1), p. 102–107.
2. Berry, RJ., et al. Folic acid fortification: neural tube defect risk reduction – a global perspective. In Folate in health and disease, 2nd ed. Bailey, LB., Ed. Boca Raton, FL, USA: CRC Press, 2010, p. 179–204.
3. Bollheimer, LC., et al. Folate and its preventive potential in colorectal carcinogenesis. How strong is the biological and epidemiological evidence? Crit Rev Oncol Hematol, 2005, 55(1), p. 13–36.
4. Botto, LD., et al. Neural-tube defects. N Engl J Med, 1999, 11, 341(20), p. 1509–1519.
5. Botto, LD., Yang, Q. 5,10-methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGE Review. Am J Epidemiol, 2000, 1, 151(9), p. 862–877.
6. Budhiraja, S., et al. Neural-tube defect in dizygotic twins. Ped Surg Intl, 2002, 8, 18(2), p. 211–212.
7. Bukowski, R., et al. Preconceptional folate supplementation and the risk of spontaneous preterm birth: a cohort study. PloS Med, 2009, 6, e1000061.
8. Busby, A., et al. Preventing neural tube defects in Europe: A missed opportunity. Reprod Toxicol, 2005, 20(3), p. 393–402.
9. Butterworth, Jr. CE., Tamura, T. Folic acid safety and toxicity: a brief review. Am J Clin Nutr, 1989, 50, 2, p. 353–358.
10. Centers for Disease Control Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects MMWR. 1992, 41(RR-14).
11. Courtemanche, C., et al. Folate deficiency inhibits the proliferation of primary human CD8+ T lymphocytes in vitro.J Immunol, 2004, 173, p. 3186–3192.
12. Czeizel, AE., Dudás, I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med, 1992, 24, 327(26), p. 1832–1835.
13. Czeizel, AE., Dobó, M., Vargha, P. Hungarian cohort-controlled trial of periconceptional multivitamin supplementation shows a reduction in certain congenital abnormalities. Birth Defects Res A Clin Mol Teratol, 2004, 70(11), p. 853–861.
14. Daly, S., et al. Minimum effective dose of folic acid for food fortification to prevent neural-tube defects. Lancet, 1997, 6, 350(9092), p. 1666–1669.
15. De-Regil, LM., et al. Effect and safety of periconceptional folate supplementation for preventing birth defect (Review). The Cochrane Library 2010; issue 10.
16. Dheen, ST., et al. Recent studies on neural tube defects in embryos of diabetic pregnancy: An overview. Curr Med Chem, 2009, 16(18), p. 2345–2354.
17. Ebbing, M., et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA, 2009, 302, p. 2119–2126.
18. Food and Drug Administration. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Final Rule. 21 CFR Parts 136, 137, and 139. Fed. Regist, 1996, 61, p. 8781–8789.
19. Frey, L., Hauser, WA. Epidemiology of neural tube defects. Epilepsia, 2003, 44(Suppl), p. 34.
20. Hibbard, BM., et al. Folic acid and reproduction. Acta Obstet Gynecol Scand, 1965, 44, p. 375–400.
21. Hirsch, S., et al. Colon cancer in Chile before and after the start of the flour fortification program with folic acid. Eur J Gastroenterol Hepatol, 2009, 21(4), p. 436–439.
22. Hubner, RA., Houlston, RS. Folate and colorectal cancer prevention. Br J Cancer, 2009, 27, 100(2), p. 233–239.
23. Christian, P., et al. Antenatal supplementation with micronutrients and biochemical indicators of status and subclinical infection in rural Nepal. Am J Clin Nutr, 2006, 83, p. 788–794.
24. Institute of Medicine Washington, DC. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline: A report of the standing committee on the scientific evaluation of dietary reference intakes and its panel on folate, other b vitamins, and choline and subcommittee on upper reference levels of nutrients. Washington, DC: National Academy Press, 2000, p. 357–373.
25. Institute of Medicine Washington, DC. Folate. In Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington, DC: National Academy Press, 1998, p. 196–305.
26. Institute of Medicine Washington, DC. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin b6, folate, vitamin B12, pantothenic acid, biotin, and choline: A report of the standing committee on the scientific evaluation of dietary reference intakes and its panel of folate, other B vitamins, and choline and subcommittee on upper reference levels of nutrients. Washington, DC: National Academies Press, 1998, p. 55–422.
27. Jedlička, P., Keller, O., et al. Speciální neurologie. Praha: Galén, 2005, p. 170–172.
28. Kibar, Z., et al. Toward understanding the genetic basis of neural tube defects. Clin Genetics, 2007, 71(4), p. 295–310.
29. Kim, Y. Folate: A magic bullet or a double-edged sword for colorectal cancer prevention? Gut, 2006, 55(10), p. 1387–1389.
30. Koren, G., et al. Folic acid: The right dose. Can Fam Physician, 2008, 54(11), p. 1545–1547.
31. Lumley, J., et al. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects. Cochrane Database Syst Rev, 2001(3):CD001056.
32. Martínez de Villarreal, L., et al. Decline of neural tube defects cases after a folic acid campaign in Nuevo León, México. Teratol, 2002, 66(5), p. 249–256.
33. Mason, JB. Folate, cancer risk, and the Greek god, Proteus: A tale of two chameleons. Nutr Rev, 2009, 67(4), p. 206–212.
34. McNulty, H., Pentieva, K. Folate bioavailability. Proceedings of the Nutrition Society, 2004, 63(4), p. 529–536.
35. Mitchell, LE., et al. Spina bifida. Lancet, 2004, 20, 364(9448), p. 1885–1895.
36. Norsworthy, B., et al. Effects of once-a-week or daily folic acid supplementation on red blood cell folate concentrations in women. Eur J Clin Nutr, 2004, 58(3), p. 548–554.
37. Pfeiffer, CM., et al. Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999–2000. Am J Clin Nutr, 2005, 82, p. 442–450.
38. Pietrzik, K., et al. Folic acid and l-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet, 2010, 48, p. 535–548.
39. Seller, MJ., Nevin, NC. Periconceptional vitamin supplementation and the prevention of neural tube defects in south-east England and Northern Ireland. J Med Genet, 1984, 1, 21(5), p. 325–330.
40. Shaw, GM., Quach, T., Nelson, V., et al. Neural tube defects associated with maternal periconceptional dietary intake of simple sugars and glycemic index. Am J Clin Nutr, 2003, 78(5), p. 972–978.
41. Solomons, NW. Food fortification with folic acid: Has the other shoe dropped? Nutrition Rev, 2007, 65(11), p. 512–515.
42. Stolzenberg-Solomon, RZ., et al. Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Clin Nutr, 2006, 83, p. 895–904.
43. Suarez, L., et al. Neural tube defects among Mexican Americans living on the US-Mexico border: Effects of folic acid and dietary folate. Am J Epidemiol, 2000, 1, 152(11), p. 1017–1023.
44. Surén, P., Roth, C., Bresnahan, M., et al. Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. JAMA, 2013, 309(6), p. 570–577.
45. Šípek, A. Počet vybraných vrozených vad u narozených dětí a u případů prenatálně diagnostikovaných v ČR v roce 2009 a 2010. Národní registr vrozených vad České republiky, 2011, 15, p. 2–4.
46. Wald, NJ., et al. Quantifying the effect of folic acid. Lancet, 2001, 15, 358(9298), p. 2069–2073.
47. Wen, SW., et al. Maternal exposure to folic acid antagonists and placenta mediated adverse pregnancy outcomes. CMAJ, 2008, 179, p. 1263–1268.
48. Wilcken, B., et al. Geographical and ethnic variation of the 677C>T allele of 5, 10-methylenetetrahydrofolate reductase (MTHFR): Findings from over 7000 newborns from 16 areas world wide. J Med Genet, 2003, 1, 40(8), p. 619–625.
49. Williams, PJ., et al. Possible roles for folic acid in the regulation of trophoblast invasion and placental development in normal early human pregnancy. Biol Reprod, 2011, 84, p. 1148–1153.
50. Wyszynski, D. Neural tube defects: From origin to treatment. New York: Oxford University Press, 2006.
51. Yang, J., et al. Socioeconomic status in relation to selected birth defects in a large multicentered US case-control study. Am J Epidemiol, 2008, 15, 167(2), p. 145–154.
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Czech Gynaecology
2014 Issue 2
Most read in this issue
- Role of prebioptic and bioptic methodsin the screening and diagnosis of cervical cancer
- Intrauterine fetal death syndrom: analysis of cases from 2008 to 2012 in Institute for the care of mother and child
- New views on the functional morphology of human clitoris
- Breech presentation – an analysis of resultsin one perinatal center